HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, detailed results from ivonescimab's chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes.

By FiercePharma · Jun 1, 2026 · via FiercePharma
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
The WeekFierceBiotech ↗
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, d…
Jun 1, 2026
AARP data show U.S. drug prices rise postlaunch as foreign prices fall
The WeekBriefing
AARP data show U.S. drug prices rise postlaunch as foreign prices fall
AARP found top U.S. brand-name drugs climbed 81% in list price since launch while prices abroad fell 13%, hint…
Jun 1, 2026
STAT+: A standing ovation for RevMed, and caution for Akeso
The WeekSTAT News ↗
STAT+: A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immun…
May 31, 2026